Company Valuation: Vaxcyte, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,354 1,256 3,787 5,976 10,610 10,610 -
Change - -7.24% 201.58% 57.79% 77.56% 0% -
Enterprise Value (EV) 1 1,354 1,256 3,787 5,976 9,429 9,229 8,699
Change - -7.24% 201.58% 57.79% 57.8% -2.12% -5.74%
P/E ratio -8.8x -12.3x -13.9x -15.2x -20.9x -19.1x -18.4x
PBR - - - - - - -
PEG 0.1x 0.3x -0.2x -0.7x 12.07x -2.02x -5.07x
Capitalization / Revenue - - - - - - 424x
EV / Revenue - - - - - - 348x
EV / EBITDA -15.4x -12.3x -16.5x -12.9x -17.3x -15.3x -11.1x
EV / EBIT -15.1x -12.1x -16.3x -12.8x -16.8x -14.6x -12.8x
EV / FCF - -9.81x -57.1x -19.1x -18.5x -16.9x -16.9x
FCF Yield - -10.2% -1.75% -5.24% -5.4% -5.9% -5.93%
Dividend per Share 2 - - - - - - -
Rate of return - - - - - - -
EPS 2 -3.02 -1.93 -3.44 -4.14 -4.068 -4.453 -4.615
Distribution rate - - - - - - -
Net sales 1 - - - - - - 25
EBITDA 1 -88.18 -101.9 -229.7 -464.9 -543.9 -603.2 -783.4
EBIT 1 -89.58 -103.7 -232.3 -468 -561.7 -631.9 -677.9
Net income 1 -89.22 -100.1 -223.5 -402.3 -490.1 -558.5 -562.6
Net Debt 1 - - - - -1,181 -1,381 -1,911
Reference price 2 26.57 23.79 47.95 62.80 85.13 85.13 85.13
Nbr of stocks (in thousands) 50,950 52,785 78,980 95,154 124,637 124,637 -
Announcement Date 3/29/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

P/E ratio, Detailed evolution

Add to a list
P/E ratio (Y) EV / Sales (Y) EV / EBITDA (Y) Yield (Y) Capi.($)
-20.93x - -17.34x-.--% 10.61B
-286.3x9.92x122.46x-.--% 117B
17.96x4.02x11.29x0.43% 71.22B
461.38x16.7x-822.67x-.--% 38.94B
-33.74x5.12x-10.99x-.--% 27.45B
-39.97x5.88x-41.38x-.--% 23.61B
17.52x3.94x11.2x1.71% 22.56B
-61.19x - - - 14.07B
-14.89x41.11x-17.77x-.--% 14.29B
26.55x3.71x18.89x-.--% 11.65B
Average 6.64x 11.30x -82.92x percentage-no-prefix 35.13B
Weighted average by Cap. -47.52x 9.48x -53.82x percentage-no-prefix
See all sector valuations

Year-on-year evolution of the PER

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. Valuation Vaxcyte, Inc.